- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05203835
Trial of Acebilustat for the Treatment of Upper Arm Lymphedema (HEAL)
April 15, 2024 updated by: Stanley Rockson, Stanford University
A Pilot Placebo-Controlled Trial of Acebilustat (CTX-4430) for the Treatment of Human Upper Extremity Lymphedema
This study is designed to investigate the response of unilateral upper extremity (arm) lymphedema, during pharmacologic treatment of lymphedema with oral placebo and oral acebilustat.
Participants will receive "study drug" (Acebilustat or placebo), for 9 months.
For 3 of these months, the participant will receive placebo; for 6 of these months, the participant will receive active ingredient, acebilustat.
The study is blinded which means that the participant will not be told which study pill they are taking.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
To enter this study, participants will have to meet requirements that will be evaluated during screening, Visit 1.
If eligible, and if they choose to continue, Visit 2, treatment start, will take place 2-7 days later.
Study visits are every (approximately) 90 days.
Physical exam, including limb measurements and skin measurements (with tape measure and dermal ultrasound) are performed.
Phlebotomy for research samples and clinical labs will be performed at study start and end of study.
Study Type
Interventional
Enrollment (Estimated)
70
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shayne Hargis
- Phone Number: 650-725-9820
- Email: heal-lymphedema-study@stanford.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94305
- Recruiting
- Stanford University
-
Sub-Investigator:
- Mark Nicolls, MD
-
Sub-Investigator:
- Wen Tian, PhD
-
Sub-Investigator:
- Xinguo Jiang, MD
-
Contact:
- Shayne Hargis
- Phone Number: 650-725-9820
- Email: heal-lymphedema-study@stanford.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Upper arm lymphedema, single arm, stage 2, greater than 6 months duration
- Male or female.
- Ages 18-75.
- Prior imaging by lymphoscintigraphy or magnetic resonance lymphangiography that confirms the presence of lymphedema in the affected limb OR, at screening, an affected:unaffected limb volume ratio of ≥1.1 with significant history of lymphedema
- Consistent use of an appropriately sized compression garment for daytime use.
- Willing to maintain a stable regimen of self-care from screening to end-of-study.
- If a potential participant has undergone prior microvascular (vascular lymph node transfer, lymphaticovenous anastomosis) or debulking surgical intervention, at least one year must have elapsed prior to screening AND, at screening, an affected: unaffected limb volume ratio of ≥1.1.
- Lymphedema therapy must be completed at least 8 weeks prior to screening.
- Has received Covid-19 vaccine (Pfizer, Moderna or Johnson & Johnson)
- Ability to understand and the willingness to sign a written informed consent document.
- . If the possibility of conception exits, agrees to use a medically acceptable method of contraception (both male and female) from the signing of the informed consent form through the entire study period; men or women who are surgically sterile (> 6 months after surgery) or women who have been postmenopausal for at least 1 year are not considered to be of childbearing potential.
Exclusion Criteria:
- Concurrent participation in a clinical trial of any other investigational drug or therapy
- Other medical condition that could lead to acute limb edema (e.g. acute blood clot) or other medical condition that could result in symptoms overlapping those of lymphedema (e.g. frozen shoulder).
- History of clotting disorder.
- Chronic (persistent) infection in the affected limb.
- Active cancer treatment or history of cancer treatment within the past 2 years, except for non-melanoma skin cancer or cervical cancer in-situ.
- Chronic kidney disease
- Liver disease
- Pregnancy or nursing.
- Substance abuse (e.g., alcohol or drug abuse) within 6 months prior to screening.
- Any current use of non-steroidal anti-inflammatory drug (NSAID), e.g. ibuprofen, ketoprofen) or prior therapeutic use of ketoprofen.
- Any current use of immunosuppressive or immunomodulatory drugs (e.g., immunosuppressants, anticancer drugs, interleukins, interleukin antagonists or interleukin receptor blockers) or leukotriene pathway inhibitor (zileuton), leukotriene receptor antagonist (e.g montelukast).
- Personal or family history of prolonged QT syndrome
- Any reason (in addition to those listed above) that, in the opinion of the investigator, precludes full participation in the study.
- Any current use of statin drugs. The use of any statin drug should be discontinued at least 2 weeks prior to the trial enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Placebo and acebilustat
Participants will take acebilustat and placebo over a period of 9 months.
|
By mouth, once a day, 100 mg capsule
Placebo to match acebilustat by mouth, once a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in ultrasonographic measurement of dermal thickness in the affected upper extremity
Time Frame: Baseline through week 36
|
Dermal thickness will be derived from an ultrasonographic examination of the skin of the forearm using a Terason 3200T device.
|
Baseline through week 36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in caliper measurement of dermal thickness in the affected upper extremity
Time Frame: Baseline through week 36
|
Dermal thickness will be derived from a caliper measurement of the skin of the forearm.
|
Baseline through week 36
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Stanley Rockson, MD, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 27, 2022
Primary Completion (Estimated)
February 28, 2025
Study Completion (Estimated)
August 31, 2025
Study Registration Dates
First Submitted
January 10, 2022
First Submitted That Met QC Criteria
January 10, 2022
First Posted (Actual)
January 24, 2022
Study Record Updates
Last Update Posted (Actual)
April 17, 2024
Last Update Submitted That Met QC Criteria
April 15, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-62051
- NCI-2022-09343 (Other Identifier: CTRP)
- BRS0140 (Other Identifier: OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphedema of Upper Arm
-
Assiut UniversityWithdrawnLymphedema | Lymphedema of Upper Arm | Mastectomy; Lymphedema
-
ThuasneInternational Clinical Trials AssociationRecruitingLymphedema of Upper ArmFrance, Turkey
-
Massachusetts General HospitalHeinz Family FoundationRecruitingBreast Cancer | Lymphedema | Edema | Lymphedema of Upper Arm | Breast Cancer Lymphedema | Breast Cancer Metastatic | Lymphedema of Upper Limb | Breast Cancer Stage | Lymphedema Arm | Edema Arm | Lymphedema of the HandsUnited States
-
Lymphatica Medtech SATerminatedLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmSwitzerland
-
CEN BiotechmediCompletedLymphedema of Upper ArmFrance
-
Maastricht University Medical CenterRadboud University Medical Center; Erasmus Medical CenterRecruitingLymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema ArmNetherlands
-
Institute of Technology, SligoSligo General HospitalUnknownLymphedema of Upper Arm
-
Duke UniversityCompletedMelanoma | Breast Cancer | Lymphedema of Upper Arm | Thoracic CancerUnited States
-
Marmara UniversityUnknownLymphedema of Upper ArmTurkey
-
Dokuz Eylul UniversityCompletedLymphedema of Upper ArmTurkey
Clinical Trials on Acebilustat
-
Celtaxsys, Inc.Quotient SciencesCompletedHeathy VolunteersUnited Kingdom
-
Stanford UniversityCompletedCovid19United States
-
Stanford UniversityCompleted